Milnacipran dose-effect study in patients with burning mouth syndrome

Clinical Neuropharmacology

Volumn 34, Issue 4, 2011, Pages 166-169

  Kato, Yuichi ^a   Sato, Tomoko ^a   Katagiri, Ayano ^a   Umezaki, Yojiro ^a   Takenoshita, Miho ^b   Yoshikawa, Tatsuya ^b   Sato, Yusuke ^a   Toyofuku, Akira ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

burning mouth syndrome; dose escalation; milnacipran; serotonin norepinephrine reuptake inhibitors (SNRI)

Indexed keywords

ETHYL LOFLAZEPATE; LORAZEPAM; MAGNESIUM OXIDE; MILNACIPRAN; MOSAPRIDE CITRATE;

ADULT; AGED; ARTICLE; BURNING MOUTH SYNDROME; CLINICAL TRIAL; CONSTIPATION; DIAPHORESIS; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; NAUSEA; OPEN STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BURNING MOUTH SYNDROME; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PAIN MEASUREMENT; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 80051550625     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318227f100     Document Type: Article

References (31)

1. Ship JA, Grushka M, Lipton JA, et al. Burning mouth syndrome: an update. JAm DentAssoc 1995;126:842-853.
2. Femiano F, Lanza A, Buonaiuto C, et al. Burning mouth syndrome and burning mouth in hypothyroidism: proposal for a diagnostic and therapeutic protocol. Oral Surg Oral Med Oral Pathol Oral RadiolEndod2008;105:e22-e27.
3. Suzuki N, Mashu S, Toyoda M, et al. Oral burning sensation: prevalence and gender differences in a Japanese population. Pain Pract 2010; 10:306-311.
4. Merskey H, Bogduk N. Classification ofChronic Pain: Descriptions ofChronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle, WA: IASP Press; 1994.
5. Patton LL, Siegel MA, Benoliel R, et al. Management ofburning mouth syndrome: systematic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103 (suppl 1):S39. e1-e13.
6. Scala A, Checchi L, Montevecchi M, et al. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral BiolMed 2003;14:275-291. (Pubitemid 44560797)
7. Lamey PJ, Lewis MA. Oral medicine in practice: burning mouth syndrome. BrDentJ 1989;167:197-200.
8. Just T, Steiner S, Pau HW. Oral pain perception and taste in burning mouth syndrome. JOralPatholMed 2010;39:22-27.
9. Sardella A, Lodi G, Demarosi F, et al. Causative or precipitating aspects of burning mouth syndrome: a case-control study. J Oral Pathol Med2006;35:466-471. (Pubitemid 44212900)
10. Sardella A, Lodi G, Demarosi F, et al. Burning mouth syndrome: a retrospective study investigating spontaneous remission and response to treatments. OralDis 2006;12:152-155.
11. López-Jornet P, Camacho-Alonso F, Lucero-Berdugo M. Quality of life in patients with burning mouth syndrome. J Oral Pathol Med 2008;37:389-394.
12. Micó JA, Ardid D, Berrocoso E, et al. Antidepressants and pain. Trends Pharmacol Sci 2006;27:348-354. (Pubitemid 43963184)
13. Toyofuku A. Efficacy of milnacipran for glossodynia patients. IntJPsych Clin Pract2003;7(suppl 1):23-24. (Pubitemid 36917066)
14. Ganzberg S. Pain management part II: pharmacologic management ofchronic orofacial pain. Anesth Prog 2010;57:114-118.
15. Atkinson JH, Slater MA, Capparelli EV, et al. Efficacy ofnoradrenergic and serotonergic antidepressants in chronic back pain. J Clin Psychopharmacol 2007;27:135-142.
16. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004.
17. Chwieduk CM, McCormack PL. Milnacipran: in fibromyalgia. Drugs 2010;70:99-108.
18. Kranzler JD, Gendreau RM. Role and rationale for the use of milnacipran in the management of fibromyalgia. Neuropsychiatr Dis Treat 2010;6:197-208.
19. Moret C, Briley M. Antidepressants in the treatment of fibromyalgia. Neuropsychiatr Dis Treat 2006;2:537-548. (Pubitemid 46321883)
20. Toyofuku A, Miyako H. A case oftemporo-mandibular disorder with fibromyalgia treated with the antidepressant, milnacipran. Hum Psychopharmacol 2004;19:357-358. (Pubitemid 39106880)
21. Yamazaki Y, Hata H, Kitamori S, et al. An open-label, noncomparative, dose escalation pilot study of the effect ofparoxetine in treatment ofburning mouth syndrome. Oral Surg Oral Med Oral Pathol OralRadiolEndod 2009;107:e6-e11.
22. Ito M, Kimura H, Yoshida K, et al. Effectiveness of milnacipran for the treatment ofchronic pain in the orofacial region. Clin Neuropharmacol 2010;33:79-83.
23. Higuchi T, Briley M. Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan. Neuropsychiatr Dis Treat 2007;3:41-58. (Pubitemid 46779921)
24. Arnold LM, Hudson JI, Wang F, et al. Comparisons of the efficacy and safety ofduloxetine for the treatment of fibromyalgia in patients with versus with out major depressive disorder. Clin JPain 2009;25:461-468.
25. Marangell LB, Clauw DJ, Choy E, et al. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses offour pooled randomized controlled trials ofduloxetine. Pain 2011;152:31-37.
26. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol 2004;19(suppl 1):S21-S25. (Pubitemid 39386316)
27. Goldman RH, Stason WB, Park SK, et al. Low-dose amitriptyline for treatment ofpersistent arm pain due to repetitive use. Pain 2010;149: 117-123.
28. Baker CB, Woods SW. Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study design. Depress Anxiety 2003; 17: 10-18. (Pubitemid 36255238)
29. Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005;255:387-400. (Pubitemid 43029828)
30. Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants. Meta-analysis of dose-effectrelationship in randomised clinical trials. Br J Psychiatry 1999;174:297-303. (Pubitemid 29179711)
31. Bajwa ZH, Simopoulos TT, Pal J, et al. Low and therapeutic doses of antidepressants are associated with similar response in the context of multimodal treatment ofpain. Pain Physician 2009;12:893-900.